Aesica Appoints VP, Business Development and Business Development Director
News Oct 31, 2014
Aesica has announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose.
Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group.
Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany.
Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. As a qualified pharmacist he holds a PhD, and is a Board member and member of the Education Committee of DCAT.
Sven Wrabletz reports to Detlef Behrens, holds a Diplom-Betriebswirt (FH) and a Bachelor of Arts in International Business Administration and joined Aesica from Clondalkin, a packaging specialist.
Commenting on the new appointments, Ian Muir, Managing Director, Finished Dose remarked: “We are very pleased that Sven Wrabletz and Detlef Behrens have joined Aesica and look forward to the strong contribution that they are set to make to generate new business growth internationally, both in terms of sales and portfolio expansion.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019